I89.0 I87.2
Conditions
Interventions
Group 1: Patients with leg oedema of various etiologies are given decongestive therapy by means of manual and apparatus lymph drainage, compression bandages, exercise therapy. A volume reduction of th
Sponsors
Bauerfeind AG - Phlebology Business Development & Medical Affairs
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Oedema of the legs: primary and secondary lymphoedema, phleboedema, lipoedema. Willingness and ability of the patient to apply intermittent pneumatic compression and to wear multi-layer compression bandages, and to follow the instructions of the doctor and the staff Age between = 18 years Presentation of the written declaration of consent to participate in the observational study after detailed information about the nature, significance, risks and scope of the observational study as well as about the expected desired and undesired effects of the treatment in the context of the observational study. Sufficient written and spoken German language skills
Exclusion criteria
Exclusion criteria: Acute deep venous thrombosis and acute thrombophlebitis Peripheral arterial occlusive disease stage III and IV according to Fontaine Decompensated heart failure and severe, non-adjustable arterial hypertension (diastolic > 100 mmHg) Acute tissue trauma, acute erysipelas (with systemic signs such as fever, reduced general condition, signs of sepsis) Pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Volume reduction of the lower extremity in ml during decongestive therapy measured by means of 3D-assisted volume reduction of the legs, using BT600. The volume of the legs is checked daily under decongestive measures. | — |
Secondary
| Measure | Time frame |
|---|---|
| Health-related quality of life under decongestive therapy measured by means of DLQI (dermatological quality of life index) and TLQ-CVI (Tübingen quality of life questionnaire). Quality of life is assessed at the time before decongestion, after decongestion and during the maintenance phase on the three days of follow-up (after one week, three weeks and six weeks). | — |
Countries
Germany
Contacts
Public ContactMichael Jünger
Klinik und Poliklinik für Hautkrankheiten der Universität Greifswald
Outcome results
None listed